

# PROVIDER Update



CONTRACTUAL | AUGUST 2, 2024 | UPDATE 24-786 | 4 PAGES

## New: 2nd Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

### Use the updates for dates of service on and after October 7, 2024

On April 9, 2024, the Health Net\* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. P&T Committee members include physicians and representatives from participating physician groups (PPGs).

The approved updates, effective October 7, 2024, are listed on pages 2-4 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net\* and Community Health Plan of Imperial Valley *Provider Participation Agreement (PPA)*.

The update includes:

- 12 new injectable medications to be added to the DOFR crosswalk.
- 11 updates and changes to injectable medication procedure codes.
- 6 updated categories.
- 3 updates for new generic drugs.

#### Additional Information

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at [provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com) > Provider Library under Quick Links, or go directly to [providerlibrary.healthnetcalifornia.com](https://providerlibrary.healthnetcalifornia.com).

Providers are encouraged to access the provider portal at [provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com) for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact Community Health Plan of Imperial Valley at 833-236-4141.

#### THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups

#### PROVIDER SERVICES

CHPIV Medi-Cal (including ECM and CS providers) – 833-236-4141

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com)

## Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Amtagvi™	Lifileucel IV suspension 72,000,000,000 cells	Therapeutic injection	
J3590	Cosentyx® IV	Secukinumab IV solution 125 mg/5 mL	Therapeutic injection	
J3590	Cosentyx® Unoready®	Secukinumab subcutaneous solution auto-injector 300 mg/2 mL	Self-injectable	Chemotherapy adjunctive <sup>1</sup>
J1323	Elrexfio™	Injection, elranatamab-bcmm, 1 mg	Therapeutic injection	Blood/blood products for hemophilia
Q5111	Udenyca Onbody™	Pegfilgrastim-cbqv on-body injector	Therapeutic injection	
90623	Penbraya™	Meningococcal ACWY (Tet Conj)-Mening B (Rcmb) vaccines for injection	Therapeutic injection	
J3490	Rivfloza™	Nedosiran sodium subcutaneous solution 80 mg/0.5 mL	Self-injectable	
Q5133	Tofidence™	Tocilizumab-bavi, biosimilar, 1 mg	Therapeutic injection	
Q5134	Tyruko®	Injection, natalizumab-sztn, biosimilar, 1 mg	Therapeutic injection	
J3490	Wainua™	Eplontersen sodium subcutaneous solution auto-injector 45 mg/0.8 mL	Self-injectable	
J3490	Zilbrysq®	Zilucoplan sodium subcutaneous solution prefilled syringe 16.6 mg/0.416 mL	Self-injectable	
J3590	Zymfentra®	Infliximab-dyyb) injection for subcutaneous use from Celltrion USA	Self-injectable	

### Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J9321	Epkinyl™	Epcoritamab-bysp injection, for subcutaneous (SC) use	Replaces C9155
J0172	Aduhelm™	Aducanumab-avwa IV solution	No longer manufactured
J1412	Balfaxar®	Injection, prothrombin complex concentrate (human), per IU of Factor IX activity	Replaces C9159
J0177	Eylea® hd	Aflibercept Injection 8 mg	Replaces J3490
J2277	Aphexda™	Motixafortide acetate, for subcutaneous injection 62 mg	Replaces J3490
J0589	Daxxify®	DaxibotulinumtoxinA-lanm, for injection and intramuscular use	Replaces C9160
J3055	Talvey™	Talquetamab-tgvs injection, for subcutaneous use	Replaces J9999
J9376	Veopoz™	Pozelimab-bbfg injection solution	Replaces J3590
J2801	Rykindo®	Risperidone, for extended-release injectable suspension and intramuscular use	Replaces J2794
J2782	Izervay™	Avacincaptad pegol intravitreal solution 2 mg/0.1 mL (20 mg/mL)	Replaces C9162
J3490	Reditrex®	Methotrexate injection, for subcutaneous use	No longer manufactured

### Category changes

The following medications has been approved to correct the secondary category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9260	Methotrexate	Methotrexate powder 1 gm in 50 mL sodium vial (p.f.), methotrexate sodium injection, 25 mg/mL	Therapeutic injection	Chemotherapy <sup>1</sup>
J9260	Methotrexate	Methotrexate powder 1 gm in 50 mL sodium vial (p.f.), methotrexate sodium injection, 25 mg/mL (not for chemotherapy)	Self-injectable	
J3590	Adbry™	Tralokinumab-ldrm injection, for subcutaneous use	Self-injectable	
J0219	Nexviazyme™	Avalglucosidase alfa-ngpt	Therapeutic injection	Home health/infusion <sup>2</sup>
J3397	Mepsevii™	Vestronidase alpha-vjbk	Therapeutic injection	Home health/infusion <sup>2</sup>
J0218	Xenpozyme™	Injection, olipudase alfa-rpcp, 1 mg	Therapeutic injection	Home health/infusion <sup>2</sup>

---

## New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J1434</b>	Focinvez™	Injection, fosaprepitant, 1 mg	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>
<b>J9249</b>	Melphalan hydrochloride injection	Injection, melphalan (apotex), 1 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J9074</b>	Cyclophosphamide injection	Injection, cyclophosphamide (sandoz), 5 mg	Therapeutic injection	Chemotherapy <sup>1</sup>

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at [www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html](http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html).

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

<sup>2</sup>When administered by a nurse in a home setting.